Innovent Biologics Inc. has announced the successful dosing of the first participant in the seventh Phase 3 clinical trial (GLORY-OSA) of mazdutide in China. Mazdutide is a dual glucagon $(GCG.UK)$ and glucagon-like peptide-1 (GLP-1) receptor agonist intended for Chinese participants with moderate-to-severe obstructive sleep apnea (OSA) and obesity. This trial aims to further explore the potential of mazdutide in managing obesity and a range of metabolic syndromes. Previous studies have shown promising results, with a Phase 2 study indicating an 18.6% weight loss compared to placebo. The results of the GLORY-OSA study are expected to be presented in the future, as the study progresses.